Yimitasvir - HEC Pharm

Drug Profile

Yimitasvir - HEC Pharm

Alternative Names: DAG 181; Yimitasvir phosphate - HEC Pharm

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator HEC Pharm
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 30 Oct 2016 HEC Pharm completes a phase I trial (Treatment-naïve) in Hepatitis C in China
  • 22 Jul 2015 HEC Pharm enters into an agreement with Sunshine Lake Pharma to manufacture and commercialise yimitasvir
  • 25 Jun 2015 Phase-I clinical trials in Hepatitis C (Treatment-naive) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top